JP2017075105A - マクロファージ活性化剤 - Google Patents
マクロファージ活性化剤 Download PDFInfo
- Publication number
- JP2017075105A JP2017075105A JP2015202454A JP2015202454A JP2017075105A JP 2017075105 A JP2017075105 A JP 2017075105A JP 2015202454 A JP2015202454 A JP 2015202454A JP 2015202454 A JP2015202454 A JP 2015202454A JP 2017075105 A JP2017075105 A JP 2017075105A
- Authority
- JP
- Japan
- Prior art keywords
- bonito
- hot water
- water extract
- macrophages
- milling
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000002540 macrophage Anatomy 0.000 title claims abstract description 41
- 239000012190 activator Substances 0.000 title claims description 13
- 239000000284 extract Substances 0.000 claims abstract description 70
- 239000004480 active ingredient Substances 0.000 claims abstract description 19
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 12
- 241000269851 Sarda sarda Species 0.000 claims description 77
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 66
- 238000003801 milling Methods 0.000 claims description 34
- 239000000843 powder Substances 0.000 claims description 24
- 239000000047 product Substances 0.000 claims description 19
- 238000011282 treatment Methods 0.000 claims description 16
- 230000004913 activation Effects 0.000 claims description 14
- 230000000242 pagocytic effect Effects 0.000 claims description 13
- 230000016396 cytokine production Effects 0.000 claims description 9
- 239000006228 supernatant Substances 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 6
- 241000269819 Katsuwonus pelamis Species 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 33
- 230000003213 activating effect Effects 0.000 abstract description 9
- 108090000695 Cytokines Proteins 0.000 abstract description 8
- 235000013376 functional food Nutrition 0.000 abstract description 8
- 230000036737 immune function Effects 0.000 abstract description 8
- 102000004127 Cytokines Human genes 0.000 abstract description 7
- 206010057249 Phagocytosis Diseases 0.000 abstract description 6
- 235000013305 food Nutrition 0.000 abstract description 6
- 239000000463 material Substances 0.000 abstract description 6
- 230000008782 phagocytosis Effects 0.000 abstract description 6
- 238000003809 water extraction Methods 0.000 abstract description 5
- 241000962514 Alosa chrysochloris Species 0.000 abstract description 3
- 229940127554 medical product Drugs 0.000 abstract 2
- 239000000428 dust Substances 0.000 abstract 1
- 238000005520 cutting process Methods 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 16
- 238000000227 grinding Methods 0.000 description 15
- 239000002158 endotoxin Substances 0.000 description 14
- 229920006008 lipopolysaccharide Polymers 0.000 description 14
- 230000014509 gene expression Effects 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 239000003112 inhibitor Substances 0.000 description 10
- 108090001005 Interleukin-6 Proteins 0.000 description 9
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 9
- 230000026731 phosphorylation Effects 0.000 description 9
- 238000006366 phosphorylation reaction Methods 0.000 description 9
- 102000004889 Interleukin-6 Human genes 0.000 description 8
- 230000009471 action Effects 0.000 description 8
- 238000000502 dialysis Methods 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 7
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 7
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 7
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 7
- 230000017306 interleukin-6 production Effects 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 102000019145 JUN kinase activity proteins Human genes 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 239000012141 concentrate Substances 0.000 description 5
- 235000008504 concentrate Nutrition 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000006433 tumor necrosis factor production Effects 0.000 description 5
- 108010067770 Endopeptidase K Proteins 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 210000003024 peritoneal macrophage Anatomy 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- 101000876610 Dictyostelium discoideum Extracellular signal-regulated kinase 2 Proteins 0.000 description 3
- 101001052493 Homo sapiens Mitogen-activated protein kinase 1 Proteins 0.000 description 3
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 3
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 3
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 102000002689 Toll-like receptor Human genes 0.000 description 3
- 108020000411 Toll-like receptor Proteins 0.000 description 3
- 229920000392 Zymosan Polymers 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 210000005007 innate immune system Anatomy 0.000 description 3
- 239000004816 latex Substances 0.000 description 3
- 229920000126 latex Polymers 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 3
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 241000972773 Aulopiformes Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 235000019688 fish Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000003973 paint Substances 0.000 description 2
- 210000003200 peritoneal cavity Anatomy 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 235000019515 salmon Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 241000192308 Agrostis hyemalis Species 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 244000075850 Avena orientalis Species 0.000 description 1
- 210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 235000007710 Grifola frondosa Nutrition 0.000 description 1
- 240000001080 Grifola frondosa Species 0.000 description 1
- 239000012825 JNK inhibitor Substances 0.000 description 1
- 229940118135 JNK inhibitor Drugs 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000000385 dialysis solution Substances 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002036 drum drying Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- -1 stick Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000007143 thioglycolate medium Substances 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
Images
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Jellies, Jams, And Syrups (AREA)
Abstract
Description
(1)カツオ削粉の熱水抽出物又はその乾燥物を有効成分とすることを特徴とする、マクロファージ活性化剤。
(2)カツオ削粉の熱水抽出物から分子量14000以下の分子を除去した処理液又はその乾燥物を有効成分とすることを特徴とする、マクロファージ活性化剤。
(3)カツオ削粉の熱水抽出物が、カツオ削粉に2〜20倍量、好ましくは10〜15倍量加水し、80〜100℃、好ましくは90℃以上に加熱して1〜5時間(好ましくは1.5〜3時間)抽出した上清液を濃縮処理した液である、(1)又は(2)に記載の剤。
(4)カツオ削粉が荒節及び/又は鰹節自体の粉砕物である、(1)〜(3)のいずれか1つに記載の剤。
(5)マクロファージ活性化が、マクロファージのサイトカイン産生促進(サイトカイン遺伝子活性化)及び/又は貪食活性促進である、(1)〜(4)のいずれか1つに記載の剤。
以下の方法で、本発明品であるカツオ削粉の熱水抽出物又はその乾燥物を有効成分とするマクロファージ活性化剤を製造した。
実施例1で作製したマクロファージ活性化剤のマクロファージ活性化機能評価確認をするため、以下の試験を実施した。なお、機能評価確認試験を実施するために、濃縮液を分子量14000以下カットオフの透析膜で透析処理後にフィルター滅菌してから用いた。
まず、ERK1及びERK2のリン酸化による活性化レベルをウエスタンブロット法によって確認した。その結果、ERK1、およびERK2ともに、カツオ削粉抽出物の作用によってリン酸化レベルが上昇することが明らかになった(図9)。また、P−38及びJNKもカツオ削粉熱水抽出物によってリン酸化レベルが上昇することが明らかになった(図10、11)。
Claims (5)
- カツオ削粉の熱水抽出物又はその乾燥物を有効成分とすることを特徴とする、マクロファージ活性化剤。
- カツオ削粉の熱水抽出物から分子量14000以下の分子を除去した処理液又はその乾燥物を有効成分とすることを特徴とする、マクロファージ活性化剤。
- カツオ削粉の熱水抽出物が、カツオ削粉に2〜20倍量加水し、80〜100℃に加熱して1〜5時間抽出した上清液を濃縮処理した液である、請求項1又は2に記載の剤。
- カツオ削粉が荒節及び/又は鰹節自体の粉砕物である、請求項1〜3のいずれか1項に記載の剤。
- マクロファージ活性化が、マクロファージのサイトカイン産生促進及び/又は貪食活性促進である、請求項1〜4のいずれか1項に記載の剤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015202454A JP6647623B2 (ja) | 2015-10-13 | 2015-10-13 | マクロファージ活性化剤 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015202454A JP6647623B2 (ja) | 2015-10-13 | 2015-10-13 | マクロファージ活性化剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2017075105A true JP2017075105A (ja) | 2017-04-20 |
JP6647623B2 JP6647623B2 (ja) | 2020-02-14 |
Family
ID=58549958
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015202454A Active JP6647623B2 (ja) | 2015-10-13 | 2015-10-13 | マクロファージ活性化剤 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6647623B2 (ja) |
-
2015
- 2015-10-13 JP JP2015202454A patent/JP6647623B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JP6647623B2 (ja) | 2020-02-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6307153B2 (ja) | 免疫バランス調整剤及び免疫バランス調整用食品組成物 | |
JPWO2006093267A1 (ja) | 免疫調節作用を有する発酵組成物 | |
JP5213332B2 (ja) | 卵由来の骨強化組成物 | |
JP7281031B2 (ja) | 加齢に伴う持続的注意力低下の改善用の組成物 | |
JP2015070855A (ja) | 発酵乳および抗ウイルス剤の製造方法 | |
JP5927191B2 (ja) | 全卵タンパク質ペプチド、その調製方法及び使用 | |
TW201410254A (zh) | 新穎蛋白質素材 | |
JP5357042B2 (ja) | 骨強化用食品素材 | |
WO2017119476A1 (ja) | 神経性疾患予防用組成物 | |
JPWO2009057281A1 (ja) | 骨芽細胞分化促進及び破骨細胞分化抑制用食品素材 | |
JP2015086214A (ja) | 免疫疾患予防剤 | |
JP2002000193A (ja) | 乳塩基性シスタチン高含有画分及びその分解物の製造法 | |
EP2612673A1 (en) | Intestine immunomodulator | |
EP3290043B1 (en) | Enzyme-treated milk product, method for producing same, composition, and product | |
JP2017075105A (ja) | マクロファージ活性化剤 | |
JP6674241B2 (ja) | 認知機能の維持または改善剤 | |
WO2017022560A1 (ja) | 形質細胞様樹状細胞増加剤 | |
KR20140106058A (ko) | 수용성 연어이리 추출물 및 식물성 유산균을 포함하는 면역 증강용 조성물 | |
JP2014148467A (ja) | 血中クレゾール低下剤 | |
JPWO2009057282A1 (ja) | 骨吸収抑制用食品素材 | |
TWI607709B (zh) | 骨強化劑 | |
JP2009298702A (ja) | 経口用組成物 | |
CN104939098A (zh) | 一种增强骨免疫力、补钙锁钙的保健食品及其制备方法 | |
WO2018062354A1 (ja) | 卵殻膜含有粉末を含む腸内フローラ改善剤および腸内フローラ改善用組成物 | |
TWI574696B (zh) | 新穎蛋白質素材 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20181001 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190910 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190930 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20191001 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191108 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20191210 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20191226 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6647623 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |